![](https://cdn.prod.website-files.com/64d5ee31f6ef966121388e81/663b473a40d638060ac975b4_2024-Q1%20update.webp)
Presentation of Q1 2024 Results
Tromsø, Norway, May 8th, 2024 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 30.0 million and an EBITDA of NOK 2.3 million for the first quarter of 2024.
![](https://cdn.prod.website-files.com/64d5ee31f6ef966121388e81/661530a8d2d3954527e4bca9_ASIB%20ArcticZymes.webp)
Joint Research with Austrian Centre of Industrial Biotechnology
Tromsø, Norway, April 9, 2024 - ArcticZymes Technologies ASA (OSE: AZT) and the Austrian Centre of Industrial Biotechnology (acib) enter a joint research project to uncover the benefits of salt active nucleases in the purification of bionanoparticles (BNP’s).
![](https://cdn.prod.website-files.com/64d5ee31f6ef966121388e81/6604230e08039a34c004c339_AZ%20R2D%20new%20ligase.webp)
Research Paper on ArcticZymes R2D Ligase Published in the Biotechnology Journal
Tromsø, Norway, March 27, 2024 - ArcticZymes Technologies ASA (OSE: AZT) Research Paper on ArcticZymes R2D Ligase™ is published in the Biotechnology Journal
ArcticZymes Technologies ASA Q4 2023 Results & Presentation
Tromsø, Norway, February 1st, 2024 – ArcticZymes Technologies (OSE: AZT) reported sales of NOK 28.4 million and an EBITDA of NOK 2.0 million for the fourth quarter of 2023.